Andrew Branagan, MD, discusses novel induction therapies being used with transplant to improve outcomes in patients with multiple myeloma.
Andrew Branagan, MD, a medical oncologist at Massachusetts General Hospital Cancer Center,discusses novel induction therapies being used with transplant to improve outcomes in patients with multiple myeloma.
The field of multiple myeloma has come a long way with regard to induction therapies, Branagan explains. While very good partial remission (VGPR) rates were previously less than 50%, they are now observed in two-thirds of patients. Some data have indicated that up to 100% of patients achieve VGPR with certain regimens, making it difficult to decide which approach to use.
Currently, the standard regimen is the combination of lenalidomide (Revlimid), bortezomib (Velcade), and daratumumab (Darzalex). Some growing data suggest that current standards will probably change in the near future, concludes Branagan.